# Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

> **NCT04887831** · PHASE2 · TERMINATED · sponsor: **G1 Therapeutics, Inc.** · enrollment: 92 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer
- Myelosuppression Adult
- Chemotherapy-induced Neutropenia
- Metastatic Bladder Cancer

## Interventions

- **DRUG:** Trilaciclib
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04887831
- **Lead sponsor:** G1 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-04
- **Primary completion:** 2023-04-07
- **Final completion:** 2024-03-01
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** Sponsor no longer pursuing trilaciclib for the indication.
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04887831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04887831, "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04887831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*